hypercholesterolemia

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.

Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antitumor effects to prevent human endothelial dysfunction induced by hypercholesterolemia and hyperglycemia.

Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1].

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia. Frovocimab is used to study hypercholesterolemia.

Lerodalcibep (LIB003), a lipid-lowering agent, consists of a PCSK9-binding domain (adnectin) fused with human serum albumin, forming a recombinant fusion protein. It is utilized in the research of hypercholesterolemia and cardiovascular diseases [1].

Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9, demonstrating lipid-lowering efficacy, and is used in research on hypercholesterolemia and hyperlipidemia [1].

Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance its degradation. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2].

Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).

Lodelcizumab (LGT 209) is a monoclonal antibody targeting the preprotein convertase Bacillus subtilis protease Kexin-9 (PCSK9) and is used to study hypercholesterolemia.